Novartis AG (NVS)
Novartis IgAN data in New England Journal of Medicine showFabhalta® slowed kidney function decline by 49.3%
Novartis IgAN data in New England Journal of Medicine showFabhalta® slowed kidney function decline by 49.3%
Change in holdings of interested parties/officers
SMCI Investors Have Opportunity to Lead Super Micro Computer, Inc. Securities Fraud Lawsuit with the Schall Law Firm
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Immidiate Report
WMK Investors Have Opportunity to Join Weis Markets, Inc. Fraud Investigation with the Schall Law Firm
Immediate Report
EVTL Investors Have Opportunity to Join Vertical Aerospace Ltd. Fraud Investigation with the Schall Law Firm
SAN Investors Have Opportunity to Join Banco Santander, S.A. Fraud Investigation with the Schall Law Firm
BW Investors Have Opportunity to Join Babcock & Wilcox Enterprises, Inc. Fraud Investigation with the Schall Law Firm